about
ConceptGen: a gene set enrichment and gene set relation mapping toolCurcumin for malaria therapyGlycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systemsLinezolid has unique immunomodulatory effects in post-influenza community acquired MRSA pneumoniaPeroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transitionEpithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients.Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor.PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancerInhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis.Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristicsPeroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair.Peroxisome proliferator-activated receptors in lung cancer.Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancerFAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1Molecular cross-regulation between PPAR-γ and other signaling pathways: implications for lung cancer therapy.Cigarette smoke and cancer.Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition.Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition.Epithelial-mesenchymal transition in tumor metastasis: a method to the madnessDifferential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype.Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer.Breaking the tolerance for tumor: Targeting negative regulators of TLR signaling.MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro.Excavation of FOSL1 in the Ruins of KRAS-Driven Lung CancerTemporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasionThe level of tyrosine kinase activity regulates the expression of p21/WAF1 in cancer cells
P50
Q24599471-C06575AD-328C-4AF5-9516-2B371B9ADDC7Q28296943-63DF125A-4EB1-400F-8F89-A8CF69454193Q28475586-6BF794E1-5B82-45B3-BD6C-1BBAEE4A6310Q28543159-92F87A91-CE90-4D20-AB0C-2A604E158902Q30498249-B12C703F-C78D-499B-80C8-8AD881F62314Q33705213-FBF27D2A-5CC1-41EA-9F51-EA3D9F194567Q34333813-90888B34-10BE-4829-AAFC-5AB58BE42E21Q34768343-CE2E4B84-38FA-4CB5-868D-EE34A786860FQ35236478-0C5B08D4-D22D-4AF3-97C7-96BFC55135D7Q35925032-AE343173-F9F7-45CA-8157-B4D7456D9754Q36097761-AD9E85CD-CDE7-4852-97CA-B598831736B8Q36284876-49BD4D59-2B65-450C-A524-50554B7B4627Q36417658-212E4FF7-1301-4197-B303-C748D6161BD4Q36661722-D8903DD5-8084-4289-9EDA-714B83FBA00AQ37482353-8EE026CC-F470-4DD1-B607-BC98564655CDQ37847515-047CAA1E-DBDF-49A9-8CE4-7866293C7B22Q38268778-7D2DC687-49BE-46A7-A833-51C82F884EDDQ38754843-29720BA2-D465-4FFD-B5FF-0062EF88FEDDQ38840291-9B7E4D04-985D-42D0-8FD3-DCF0EADC387BQ38856280-9B31A2D4-BC08-4F34-8B3E-065C5D256B9AQ39899493-51946A87-E292-4984-86D6-C3A20A323B26Q39936158-9A0E3EE8-6015-476B-8015-5290ADA4158BQ40283971-CFD6164D-930D-45C9-9F75-B400D0979F07Q40601264-B1CD7939-D39B-47C1-A85D-63AC62A6CDDAQ42214163-8F7EE1FD-269E-4440-9A6C-38060CA4C8ECQ44010956-046394CA-1228-4614-AE6C-F60B3DCB8FEDQ50087304-B6381FE0-D6CA-4819-BE34-0DD1DBA6CF6BQ50865600-E366763D-D2B0-4CAC-BB2D-91C3E0F31BEFQ57095042-868A21C8-827B-45D0-BA14-72CFD26E2B1DQ74237951-5A1EB419-5AF1-4BC8-99D5-7A366CF1B00BQ77990150-C7BAC38A-1E2E-48FB-8D53-4FE62855793A
P50
description
researcher, ORCID id # 0000-0003-1947-791X
@en
wetenschapper
@nl
name
Venkateshwar G Keshamouni
@ast
Venkateshwar G Keshamouni
@en
Venkateshwar G Keshamouni
@nl
type
label
Venkateshwar G Keshamouni
@ast
Venkateshwar G Keshamouni
@en
Venkateshwar G Keshamouni
@nl
prefLabel
Venkateshwar G Keshamouni
@ast
Venkateshwar G Keshamouni
@en
Venkateshwar G Keshamouni
@nl
P106
P31
P496
0000-0003-1947-791X